Veracyte completed the acquisition of Decipher Biosciences for $600m.

Veracyte, a global genomic diagnostics company, completed the acquisition of Decipher Biosciences, a commercial-stage precision oncology company, for $600m. "By combining Decipher Biosciences’ leadership in urologic cancers with our comprehensive genomic testing menu, Veracyte will be able to serve patients across the clinical care continuum in 7 of the 10 most prevalent cancers in the United States with highly differentiated and clinically impactful tests, significantly accelerating revenue growth and driving shareholder value. Further, with our best-in-class nCounter diagnostics platform, we are well-positioned to deliver comprehensive genomic cancer testing to physicians and their patients worldwide," Bonnie Anderson, Veracyte Chairman and CEO.